ARCHIVES

Kadcyla Extends Median PFS In Open-Label Phase III Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Avon Gives $3 Million To Expand CDC’s Screening Program

February 18, 1994

FDA Advisors Recommend Approval Of Leucovorin, Hexamethylmelamine

June 16, 1989

NCI Needs $107 Million More In FY 1982 Than Asked for Key Programs, R01s And P01s, New Initiatives

April 17, 1981

AACR Presents Awards at Annual Meeting

April 5, 2013

Civin Moves From Hopkins To Maryland To Direct Stem Cell Medicine Center

January 9, 2009

1st Cancer Patients Treated With Gene Therapy At NIH

February 1, 1991